BLAINJECTIONINJECTABLEPriority Review
Approved
Dec 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
5/8 — Partial
Priority Review
KANUMA (sebelipase alfa) by AstraZeneca is (lal) enzyme. Approved for lysosomal acid lipase deficiency, wolman disease, cholesterol ester storage disease. First approved in 2015.
Drug data last refreshed Yesterday
Mechanism of Action
(LAL) enzyme. The primary site of action of the LAL enzyme is the lysosome, where the enzyme normally causes the breakdown of lipid particles, including LDL-c and triglycerides. Deficient LAL enzyme activity results in progressive complications due to the lysosomal accumulation of cholesteryl…
Pharmacologic Class:
Hydrolytic Lysosomal Cholesteryl Ester-specific Enzyme
Indications (3)
Worked on KANUMA at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.